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Cerebral cavernous malformations (CCM) are hamartomatous vascular malformations characterized by abnormally
enlarged capillary cavities without intervening brain parenchyma. They cause seizures and focal neurological deﬁcits
due to cerebral hemorrhages. CCM loci have already been assigned to chromosomes 7q (CCM1), 7p (CCM2), and
3q (CCM3) and have been identiﬁed in 40%, 20%, and 40%, respectively, of families with CCM. Loss-of-function
mutations have been identiﬁed in CCM1/KRIT1, the sole CCM gene identiﬁed to date. We report here the iden-
tiﬁcation of MGC4607 as the CCM2 gene. We ﬁrst reduced the size of the CCM2 interval from 22 cM to 7.5 cM
by genetic linkage analysis. We then hypothesized that large deletions might be involved in the disorder, as already
reported in other hamartomatous conditions, such as tuberous sclerosis or neuroﬁbromatosis. We performed a high-
density microsatellite genotyping of this 7.5-cM interval to search for putative null alleles in 30 unrelated families,
and we identiﬁed, in 2 unrelated families, null alleles that were the result of deletions within a 350-kb interval
ﬂanked by markers D7S478 and D7S621. Additional microsatellite and single-nucleotide polymorphism genotyping
showed that these two distinct deletions overlapped and that both of the two deleted the ﬁrst exon of MGC4607,
a known gene of unknown function. In both families, one of the two MGC4607 transcripts was not detected. We
then identiﬁed eight additional point mutations within MGC4607 in eight of the remaining families. One of them
led to the alteration of the initiation codon and ﬁve of them to a premature termination codon, including one
nonsense, one frameshift, and three splice-site mutations. All these mutations cosegregated with the disease in the
families and were not observed in 192 control chromosomes. MGC4607 is so far unrelated to any known gene
family. Its implication in CCMs strongly suggests that it is a new player in vascular morphogenesis.
Introduction
Cerebral cavernous malformations (CCM [MIM
116860]) are vascular malformations, mostly located
within the CNS. They are characterized by abnormally
enlarged capillary cavities without intervening brain pa-
renchyma (Russel and Rubinstein 1989). The most com-
mon symptoms are seizures and neurological deﬁcits due
to focal hemorrhages (Rigamonti et al. 1988; Robinson
et al. 1991; Labauge et al. 1998). The prevalence of the
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condition has been estimated to be ∼0.1%–0.5%, on the
basis of cerebral magnetic resonance imaging (MRI) and
autopsy studies of large cohorts of patients (Otten et al.
1989). Cavernous angiomas can occur in a sporadic or
autosomal dominantly inherited form. The proportion of
the familial form has been estimated to be as high as
50% in Hispanic American patients with CCM (Riga-
monti et al. 1988) and ∼10%–20% in white patients (E.
Tournier-Lasserve, unpublished data). Familial cases
are characterized by the presence of multiple lesions,
whereas sporadic cases usually harbor only one CCM
lesion (Rigamonti et al. 1988; Labauge et al. 1998).
Three CCM loci have been mapped—on 7q (CCM1),
7p (CCM2), and 3q (CCM3)—with 40% of kindreds
with CCM showing linkage to CCM1, 20% showing
linkage to CCM2, and 40% showing linkage to CCM3
(Dubovsky et al. 1995; Craig et al. 1998; Dupre et al.
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2003). To date, only one CCM gene, CCM1/KRIT1, has
been identiﬁed (Laberge-le Couteulx et al. 1999; Sahoo
et al. 1999). Nearly 100 different KRIT1 germline mu-
tations have been detected in families with CCM. All
these mutations lead to premature stop codons through
either nonsense, splice-site, frameshift, or false missense
mutations, strongly suggesting that Krit1 loss of func-
tion is the most likely mechanism in patients with CCM
(Laberge-le Couteulx et al. 1999; Sahoo et al. 1999;
Eerola et al. 2000; Zhang et al. 2000; Davenport et al.
2001; Lucas et al. 2001; Sahoo et al. 2001; Cave-Riant
et al. 2002; Chen et al. 2002; Couteulx et al. 2002;
Verlaan et al. 2002; Laurans et al. 2003; Lucas et al.
2003; Marini et al. 2003; Musunuru et al. 2003; Xu et
al. 2003).
In the present study, we identiﬁed MGC4607 as the
CCM2 gene. In a ﬁrst step, a genetic linkage analysis
conducted on ﬁve families without linkage to CCM1
excluded linkage to CCM3 and showed consistent link-
age to CCM2, allowing us to reﬁne the 22-cM CCM2
interval, published elsewhere (Craig et al. 1998), to a
7.5-cM interval. In a second step, we performed a high-
density microsatellite genotyping of this 7.5-cM interval
in the 5 initial families and in 25 additional families
with CCM, to search for putative null alleles, on the
basis of the hypothesis that large deletions may be in-
volved in this condition, as reported elsewhere for other
loci in hamartomatous conditions such as tuberous scle-
rosis or neuroﬁbromatosis types 1 and 2 (Viskochil et
al. 1990; The European Chromosome 16 Tuberous Scle-
rosis Consortium 1993; Trofatter et al. 1993). This
search led us to identify two distinct overlapping de-
letions in two unrelated families. These two deletions
were both shown to delete exon 1 of MGC4607, a
known gene of unknown function. In addition to these
two deletions, molecular analysis of the 10 exons and
intron-exon boundaries of MGC4607 revealed eight dif-
ferent small germline mutations cosegregating in eight
families of this panel. Five of these mutations led to a
premature stop codon, and one of them altered the ATG
initiator codon, strongly suggesting that CCM2 lesions
are the consequence of MGC4607 haploinsufﬁciency.
These data establishMGC4607, a gene unrelated to any
known gene family, as a new player in vessel develop-
ment and/or maturation.
Patients, Material, and Methods
Patients and Families
Thirty unrelated families were enrolled in this study,
on the basis of the following three criteria: (1) each pro-
band had at least one affected relative and/or had mul-
tiple cerebral cavernous angiomas, (2) the families of the
probands were potentially informative for a study de-
signed to identify large genomic deletions on the basis
of the identiﬁcation of microsatellite null alleles, and (3)
results of molecular screening for aKRIT1mutationwere
negative. CCM diagnosis was based on cerebral MRI
features and/or pathological analysis. We considered as
“affected” all individuals showing cavernous angiomas
on cerebral MRI, regardless of their clinical status. We
considered as “healthy” all individuals with normalMRI
results. Those who did not undergo MRI were classiﬁed
as “unknown” (ﬁg. 1).
This panel of 30 families included (1) 5 large families
potentially informative for linkage analysis, on the basis
of the number of their available meioses (families C004,
C020, C039, C049, and C116) and (2) 25 families that
included a smaller number of sampled individuals but
which were potentially informative for the search of pu-
tative null alleles. In the ﬁve large families, previous hap-
lotype analysis with KRIT1 peri- and intragenic markers
had ruled out KRIT1/CCM1 linkage (Laberge et al.
1999 and data not shown).
DNA and RNA Extraction
Genomic DNA from probands and consenting relatives
was extracted from peripheral blood by use of standard
procedures. Genomic DNA from 96 unrelated healthy
white French individuals was available as a control group.
Total RNA was extracted from lymphoblastoid Epstein-
Barr virus (EBV) cell lines for 26 of the 30 probands
(lymphoblastoid cell lines were not available for probands
C077, C096, C114, and C146), and cDNA was prepared
according to standard procedures (Laberge-le Couteulx
et al. 1999).
Genetic Markers
For the initial genetic linkage analysis, we used a panel
of 32 microsatellite markers, including 15 markers span-
ning the CCM2 interval published elsewhere (22-cM in-
terval ﬂanked by D7S516 and D7S1818) and 17 micro-
satellites spanning the CCM3 interval (22-cM interval
ﬂanked by D3S3053 and D3S1262) (Craig et al. 1998).
The distances between those markers ranged between 1
and 4 cM. TheCCM2markers were D7S2564, D7S516,
D7S2496, D7S2252, D7S2250, D7S2251, D7S2497,
D7S510, D7S485, D7S521, D7S2548, D7S691,
D7S478, D7S1818, and D7S2422 (in pterrcen orien-
tation). The CCM3 markers were D3S3530, D3S1580,
D3S3686, D3S1262, D3S3592, D3S3609, D3S3730,
D3S3715, D3S3676, D3S3520, D3S3725, D3S1574,
D3S1282, D3S1614, D3S3622, D3S1264, andD3S3673
(in pterrcen orientation) (Centre d’Etude du Polymorph-
isme Humain; Cooperative Human Linkage Center; En-
trez Genome).
Once the CCM2 region was reﬁned to a 7.5-cM in-
terval, an additional series of 12 microsatellites spanning
this reduced interval (average spacing ∼600 kb) were
used for high-density microsatellite genotyping. This
Figure 1 Genealogical trees of the 30 analyzed families with CCM. The family numbers are indicated above each pedigree. The ﬁve
families used for genetic linkage analysis were families C004, C020, C039, C049, and C116.
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Table 1
PCR Primers Used for Mutation Detection in the MGC4607 Gene
EXON(S)
OLIGONUCLEOTIDE SEQUENCE
PRODUCT
SIZE
(bp)Forward Reverse
1a TCGAGCATGTAGCGGCTG ACCACAGCAGTAGGACGC 139
2a CCATAGGTACAACACAAAGC TTTGGCAGGCACGTCCTG 274
3a TAGTGATGGTGGTGTTGGC AAGAGTACAGGGACCAAGG 216
4Aa GCCAGCACAATATTCTCAG CCTGAGGATGATATCCTCC 194
4Ba TCAGCCTGTCTGCGTACAA TCACACATGTACTCCTTAGG 188
5a CCTTCCACTGTGCTAAACT GGAGCCAGTTCTGAGTAAG 215
6a TCCAGCCAGACTGACCGA ACTGCAGTAGCCCCTCCT 235
7a ACTCAAAATGCCTCCCCAC CACCAGACAACGCATTTGG 180
8a ACGTGTGTGGGATGGAGG CCCCCTCCCTCATGCAG 215
9Aa ACTCTTGCCTACTGTGCCCA TAGAGCTGCCGCAGGTTGAT 159
9Ba GCTGTCATCACAGGAGATCC ACATTCCCAGGAGGGATCAG 199
10Aa TGAGAGAAGAGCTGAGTGG AACTGGATGTGGTGCTCAG 203
10Ba TCATGACAGCTTTGGCAG ATGACGACTGCGCGGAAG 240
1–10b GCGGCGATATGGAAGAGG CATCCACTGTCCATCATGC 1,356
1–6b GCGGCGATATGGAAGAGG ATCGCTGTGCAGGGACAG 755
2–8b CCAGACAGACTGCTGAGC ATGGTCTTGCTGTGGGG 750
6–10b TCCACCATCGACTTTCTGG CATCCACTGTCCATCATGC 679
a PCR primer used for genomic exon-by-exon ampliﬁcation and mutation detection by SSCP
and/or direct sequencing.
b RT-PCR primer used for cDNA studies.
panel included markers D7S1526, D7S678, D7S667,
D7S478, D7S2427, D7S621, D7S2248, D7S519,
D7S1800, D7S670, D7S665, and D7S2506 (ﬁg. 3A).
Last, screening for di-, tri-, and tetranucleotide tracks
of ad hoc genomic sequences spanning the D7S478–
D7S621 interval (BACs AC004854, AC004847,
AC013416, and AC004844) (ﬁg. 3A and 3B) identiﬁed
two new CA repeat markers designated MS004844
(BAC AC004844/nts 125763–125790) and MS004847
(BAC AC004847/nts 45874–45907).
In addition, 42 SNPs located between D7S478 and
MS004844 were retrieved from the National Center for
Biotechnology Information (NCBI [Entrez Genome])
and The Chromosome 7 Annotation Project databases;
the SNP designations begin with “rs” (Single Nucleotide
Polymorphism Web site).
Genotyping
Microsatellite genotyping and genetic linkage analysis
were performed as described elsewhere (Laberge et al.
1999). Pairwise LOD scores were calculated with the
MLINK program of the LINKAGE 5.1 package through
use of the following parameters: autosomal dominant
inheritance, 95% penetrance, disease gene frequency
1/1,000, and phenocopy rate 1/100. Haplotypes were
constructed using the most parsimonious linkage phase.
SNPs were screened by direct sequencing of potentially
informative individuals within families.
MGC4607 Mutation Screening
In a ﬁrst step, genomic DNA of probands of all fami-
lies was screened using SSCP, except for probands from
families C116 and C127. MGC4607 (GenBank acces-
sion number NM_031443) contains 10 coding exons.
We designed 13 sets of oligonucleotide primers from
chromosome 7 genomic contig NT_007819 (GenBank
GI number 29796755) to amplify the MGC4607 exons
and ﬂanking splice sites (primer sequences shown in ta-
ble 1). PCR and SSCP were conducted as described else-
where (Cave-Riant et al. 2002). We tested all conﬁrmed
mutations for cosegregation with the affected phenotype
in each family. Ninety-six unrelated spouses were sys-
tematically used as negative controls.
In a second step, all probands in whom we did not
detect a MGC4607 mutation were sequenced to search
for mutations through use of cDNA, when available, or
of genomic DNA. cDNA was ampliﬁed using two sets
of primers amplifying fragments from exons 2–8 and 6–
10 (table 1). Amplicons were checked on agarose gels
and were sequenced on an ABI 3100 (PE Applied Bio-
systems). Because of the existence of an alternatively
spliced transcript deleted from exon 2 in EBV cell lines,
exons 1 and 2 were ampliﬁed and sequenced from ge-
nomic DNA from all probands.
In addition to this genomic and cDNA screening, the
putative aberrant splicing effects of all mutations were
systematically tested by sequencing RT-PCR products
obtained with primers located 2 exons upstream and
downstream of the mutation location.
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Figure 2 D7S2427 parental noncontribution within family C116. The family C116 genealogical tree and CCM2 haplotypes are shown;
markers D7S516 and D7S1818 ﬂanking the published 22-cM CCM2 interval are indicated, as well as D7S691, the new telomeric boundary.
A null allele was detected at the D7S2427 marker (boxed) within the haplotype cosegregating with CCM (gray), strongly suggesting the existence
of a deletion that was conﬁrmed by a distinct D7S2427-speciﬁc primer set and by additional genotyping (ﬁg. 3).
Multiple-Tissue cDNA Panels and RT-PCR
Two sets of primers were designed to amplify
MGC4607 cDNA in two overlapping fragments span-
ning exons 1–6 (755 bp) and exons 6–10 (679 bp). Hu-
man normalized multiple-tissue cDNA (MTC I [Clon-
tech]) panel and cDNA from control EBV lymphoblasts
were ampliﬁed with these two MGC4607 primer pairs
and with primers speciﬁc for the b-actin gene (forward,
5′-CCAGATCATGTTTGAGACCT-3′; and reverse, 5′-
ACGTCACACTTCATGATGGA-3′).
Multiple-Tissue Northern Blot
A 1,332-bp cDNA probe of the full length MGC4607
ORF was generated from a lymphoblastoid EBV cell line
derived from a normal healthy control individual (frag-
ments 1–10) (table 1) and cloned in pGEM-T Easy Vec-
tor System (Promega). Probe sequence was identical to
the reported human sequence (GenBank accession num-
ber NM_031443). One hundred nanograms of the full-
length cDNA fragment was radiolabeled with [32P]-
dCTP and was used to hybridize in ExpressHyb solution
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Figure 3 Large deletions within the CCM2 interval. A, D7S2427 deletion in family C116. The 12 microsatellites located between D7S691
and D7S1818 are shown. Marker D7S2427, showing a null allele in family C116, is underlined. Markers D7S478 and D7S621 are boxed.
Affected individual genotypes in family C116 were heterozygous for those two markers. Overlapping BACs containing the region of interest
are represented with schematic bars. B, CCM2 deletion reﬁnement. MS004847 and MS004844 are indicated, as are the 42 SNP (“rs”) markers
retrieved from annotations of genomic sequence contigs. Dots denote null alleles detected with SNP markers; circled dots denote null alleles
detected with markers D7S2427 and MS004847; vertical bars denote heterozygosities at given markers. Analysis of all 30 families with markers
MS004844 and MS004847 (underlined) identiﬁed an additional null allele in family C127. Family C116 and C127 deletions were overlapping
in a 12–29-kb region; the region of overlap contains the ﬁrst exon of MGC4607.
(Clontech) at cpm/ml, a human adult mul-61–2# 10
tiple-tissue northern blot (MTN I [Clontech]), according
to manufacturer instructions. The same blot was sub-
sequently stripped and hybridized with a control human
b-actin probe (Clontech) to ensure that the RNA signal
intensity was the same in each lane. Kodak ﬁlm was
exposed with the blot at 80C for 96 h for MGC4607
and for 6 h for the b-actin probe.
Results
CCM2 and CCM3 Linkage Analysis
The ﬁve larger families, C004, C020, C039, C049,
and C116, were consistent with linkage to the CCM2
locus. No recombinant was observed with several mark-
ers located in the centromeric part of the CCM2 interval
published elsewhere (Craig et al. 1998), and the com-
bined maximum two-point LOD score at D7S478 was
5.43 at . It is interesting that CCM2 haplotypevp 0.00
analysis led us to identify two affected individuals within
pedigrees C020 and C039 who were recombinant from
D7S516 to D7S691. These recombinant events allowed
us to reduce the size of the interval to 7.5 cM, the interval
now bracketed by D7S691 and D7S1818, the CCM2
centromeric boundary identiﬁed elsewhere (Craig et al.
1998).
CCM3 marker genotyping excluded linkage to this lo-
cus in all ﬁve families. In each of the ﬁve families, there
was at least one affected individual who was recombinant
on the whole CCM3 interval. Multipoint LOD score val-
ues obtained with a panel of ﬁve markers covering the
CCM3 interval (D3S1614, D3S3676, D3S3730,
D3S3592, andD3S3686) were2 all along the interval.
D7S2427 Deletion in Family C116
We then hypothesized that large deletions might be
involved in CCM, as already reported for other hamar-
tomatous conditions, such as tuberous sclerosis or neu-
roﬁbromatosis. An additional panel of 12 microsatellite
markers located within the D7S691–D7S1818 interval
was used to study segregation patterns within all 30
families, to identify putative null alleles (ﬁg. 2; ﬁg. 3A).
The ﬁrst 11 markers did not detect any abnormality,
whereas apparent non-Mendelian inheritance was ob-
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Table 2
MGC4607 Mutations
Pedigree Location Genomic DNAa Mutation Effect on cDNA
C116 … Deletion involving at least exon 1 Detection of only one transcribed allele
C127 … Deletion involving at least exon 1 Detection of only one transcribed allele
C038 Exon 1 nt 1ArG Mutation of the initiation codon
C039 Intron 3 nt 2881GrA Exon 3 deletion
C037 Exon 4 IVS3_exon 4 junction: delAGGTACAG insCTCAGGTGGCCCT Exons 3 and 4 deletion, frameshift, and PTC
C096 Exon 5 nt 495_496insC Direct frame-shift and PTC
C002 Exon 5 nt 593TrG Missense mutation at codon 198
C004 Exon 5 nt 609GrA Exon 5 deletion, frameshift, and PTC
C020 Exon 6 nt 652CrT Nonsense mutation at codon 218
C047 Exon 10 nt 1248_1249delAG Direct frame-shift and PTC
a Numbering of MGC4607 nucleotides is according to the full-length cDNA (GenBank accession number NM_031443), beginning
nucleotide numbering at A of the ATG initiator codon.
served for the last one, marker D7S2427, in family C116
(ﬁg. 2). Patient III3 in that family looks homozygous
and failed to inherit an allele from his homozygous ob-
ligate carrier mother (patient II9), suggesting the ex-
istence of a null allele; analysis of the other members
of the family strongly supported the existence of a null
allele cosegregating with the disease (ﬁg. 2). The same
family did not exhibit incompatible genotypeswith other
markers, thus eliminating inaccurate paternity informa-
tion and sampling error as a source of incompatibility.
Failure to amplify one allele can be caused by a poly-
morphic base in the sequence corresponding to the prim-
ers used to amplify the locus. Therefore, new primers
were designed to amplify D7S2427, but the previously
observed incompatibilities persisted, strongly suggesting
the existence of a deletion at this locus in family C116.
In contrast, genotypes for the next two ﬂankingmarkers,
D7S478 and D7S621, were heterozygous and were com-
patible with the family structure, deﬁning a maximum
deleted region of 350 kb ﬂanked by those two markers.
In each of the remaining 29 families, there was at least
one affected individual who was heterozygous at
D7S2427, which allowed us to exclude a deletion at that
marker.
Detection of an Additional Deletion within Family
C127
To reﬁne the critical 350-kb deletion interval and to
screen for putative deletions in the other families, two
informative CA repeats located between D7S478 and
D7S621—MS004844 and MS004847—were genotyped
in all 30 families. In family C116, a null allele cosegre-
gating with the affected phenotype was observed with
MS004847, whereas, for MS004844, heterozygous af-
fected members were identiﬁed (ﬁg. 3B). Another
MS004847 null allele cosegregating with the disease was
detected in family C127 (ﬁg. 3B). The MS004847 null
alleles were conﬁrmed with a new set of primers.
MS004847 screening identiﬁed at least one heterozygous
affected individual in each of the 28 remaining families,
allowing us to exclude a deletion at that marker.
CCM2 Deletions Reﬁnement
To further characterize the C116 and C127 deletions
and their region of overlap, 42 SNPs located between
D7S478 and MS004844 were genotyped in both fami-
lies. In family C116, non-Mendelian inheritance com-
patible with a null allele was observed with rs1968075,
as well as with ﬁve markers located between rs1968075
and D7S2427 (rs7792760, rs3735484, rs3735485,
rs4724339, and MS004847), whereas genotypes for the
most distant ﬂanking markers, D7S478 and rs4724344,
were heterozygous and compatible with the family struc-
ture (ﬁg. 3B). These data were consistent with a deletion
with an estimated size of 81–120-kb, encompassing part
or all exons of two known genes, MGC4607 and Myo-
sin1G, and of two putative genes, XM_212099 andXM_
212101. In family C127, null alleles cosegregating with
the disease were observed with rs4724339, rs4724350,
and six internal markers (MS004847, rs4551245,
rs4724344, rs4724347, rs4724348, and rs4724349),
whereas genotypes for the most distant markers, SNP
rs12108 and MGC4607 exon 4 nt358G/A, were het-
erozygous in some affected patients. That deletion had
an estimated size of ∼25.5–81 kb and encompassed part
of one known gene, MGC4607, and one putative gene,
XM_212099 (ﬁg. 3B). In conclusion, the two deletions
observed in families C116 and C127 overlapped over
an interval, estimated at 12–29 kb, thus deﬁning our
new critical interval (ﬁg. 3B).
MGC4607 Point Mutations
The ﬁrst coding exon of two different genes maps
within this new critical interval, including one known
gene designated MGC4607 (GenBank accession number
NM_031443) and one putative gene, designated XM_
212099. The putative gene XM_212099 includes two
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Figure 4 MGC4607 point mutations. A, MGC4607 genomic organization. The 10 MGC4607 exons are numbered and are indicated by
vertical hatches. The ATG initiator codon is included in the ﬁrst exon, and the TGA stop codon in the 10th (last) exon. The locations of the
eight different MGC4607 point mutations are indicated by arrows. B, Genomic wild-type and mutated alleles in families harboring point
mutations. Family numbers are given above the mutation. F p forward primers; R p reverse primers.
exons, of which only the ﬁrst is coding. We used SSCP
to screen the coding exon in the 28 probands without
any identiﬁed CCM2 deletion, and we did not detect any
abnormal conformer (data not shown). The second gene,
MGC4607, comprises 10 coding exons (see next para-
graph). MGC4607 point mutations were identiﬁed in
eight probands (table 2; ﬁg. 4). Proband C038 harbored
a mutation within the initiating ATG codon (nt 1ArG).
Proband C039 had a splice-site mutation within intron
3 (nt2881GrA), leading to a transcript deleted of exon
3. Proband C037 had a deletion/insertion at the bound-
ary between IVS3 and exon 4, leading to a transcript
deleted of exons 3 and 4 with a PTC. Two probands
harbored mutations leading to a direct frameshift and a
premature stop codon (C096/exon 5/nt 495_496insC;
C047/exon10/nt 1248_1249delAG). Proband C002 har-
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Figure 5 MGC4607 expression analysis through use of RT-PCR.
The expression of MGC4607 transcripts was analyzed by RT-PCR
through use of the cDNA MTC1 panel (Clontech). Upper panel,
MGC4607. Lower panel, b-actin.Lane 1,100-bp ladder.Lane 2,Brain.
Lane 3, Heart. Lane 4, Skeletal muscle. Lane 5, Kidney. Lane 6, Liver.
Lane 7, Pancreas. Lane 8, Lung. Lane 9, Placenta. In all tested cDNAs,
two populations of MGC4607 transcripts existed, although at a dif-
ferent level, containing exon 2 (fragment from exons 1–6: 755 bp) or
not containing exon 2 (fragment without exon 2: 581 bp).
bored a nucleotide substitution leading to a missense
mutation within exon 5 (nt 593TrG/aa 198LeurArg).
Proband C020 harbored a nonsense mutation at codon
218 within exon 6 (nt 652CrT). Proband C004 had an
exonic nucleotide substitution that replaces the last base
of the exon 5 (nt 609GrA). That mutation is theo-
retically predicted to lead to a wobble at codon 203
(AAGrAAA/LysrLys), but it was quite surprising that
this mutation led to an abnormal splicing of exon 5 and
a PTC. For probands of families C116 and C127, se-
quencing of ampliﬁed cDNA showed that only one
MGC4607 allele was transcribed. Indeed, those two in-
dividuals, who were heterozygous at the genomic DNA
level for a polymorphism located within exon 4, showed
only one allele at the cDNA level.
In summary, a total of 10 differentmutations, including
2 large deletions and 8 point mutations, have been ob-
served in this panel of 30 families with CCM. All these
mutations cosegregated with the CCM disease phenotype
within the respective families and were not detected in
192 control chromosomes from subjects with a similar
ethnic background.
In addition to these mutations, four different exonic
variants were also identiﬁed and were considered as
polymorphic variants, since they were detected at least
once in one healthy control individual. One of those
variants had been reported elsewhere in databases
(rs2289367, substitution nt 915GrA in exon 8, ACG/
ACA Thr305Thr) (Entrez Genome). The last three
were novel substitutions (substitutions nt 126GrA
(Leu42Leu), nt 157GrA (Val53Ile) in exon 2, and nt
358GrA (Val120Ile) in exon 4.
Structure of the MGC4607 Gene, cDNA, and
Predicted Protein
MGC4607 cDNA and genomic structures have been
reported in several genome databases with 1100 re-
ported ESTs (Entrez Genome; Center for Applied Gen-
omics databases [ref C7orf22]; GenBank [accession num-
ber NM_031443]). It extends over 76 kb and includes
10 coding exons. The coding portion of the cDNA is
1,332 bp long and encodes for a 444-aa predicted pro-
tein. The ATG initiating codon is located in the ﬁrst exon
and is preceded 64 bp upstream by an inframe stop
codon. Exon 1 is embedded in a 1,086-bp CpG island.
A search of databases did not result in identiﬁcation of
any paralog but identiﬁed several orthologs in various
vertebrate species, including Mus musculus (MGC37115,
94.6% identity at the protein level with MGC4607) and
Rattus norvegicus (GenBank accession number XP_
223622). Partial homologous transcripts also have been
reported for Sus scrofa (Ss.12675), Bos taurus (Bt. 7707),
Gallus gallus (clone pgm2n.pk012h10), Danio rerio
(ENSDARG00000013705), and Fugu rubripes (SIN-
FRU00000133870) (Ensembl). We did not identify or-
thologs in invertebrates, including Drosophila and Cae-
norhabditis elegans (HomoloGene).
Searches of protein databases (ExPASyMolecular Bio-
logy Server) with Homo sapiens MGC4607 amino acid
sequence did not reveal a signal sequence, transmem-
brane domain, or any other functional or conserved do-
main, except for a phosphotyrosine interaction domain
in the N-terminal half of the protein (aa 67–223), con-
served in other homologous species (NCBI Conserved
Domain database).
MGC4607 Expression Analysis
RT-PCR analysis with a human normalized multiple-
tissue cDNA panel (MTC I [Clontech]), in addition to
cDNA from control EBV lymphoblasts, showed that
MGC4607 was expressed in all tissues tested, in agree-
ment with the expression pattern that can be deduced
from the multipleMGC4607 EST reported in the dBEST
database. In all tested cDNAs, two populations of tran-
scripts were found that differed by the absence or pres-
ence of exon 2, as reported in various ESTs (ﬁg. 5) (e.g.,
ESTs BM912546, BX337466, and BX365022). This
splicing event preserves the MGC4607 ORF, since exon
2 is composed of 174 nucleotides. Northern blot analysis
conﬁrmed this ubiquitous expression. A band of ∼1.8
kb was detected in all tissues tested, although at a dif-
ferent level (ﬁg. 6), consistent with the 1,837-bp size of
MGC4607 cDNA reported in databases (GenBank ac-
cession number NM_031443).
Discussion
We have identiﬁed MGC4607 as the CCM2 gene, on the
basis of the identiﬁcation, in 10 unrelated families with
CCM, of 10 distinct mutations within this gene. The na-
ture of thesemutations strongly suggests that at least some
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Figure 6 MGC4607 northern blot analysis. Human adult MTN
(human, 12 lanes [Clontech]) was hybridized with an MGC4607 (up-
per panel) and b-actin (lower panel) human cDNA probe. Lane 1, Brain.
Lane 2, Heart. Lane 3, Skeletal muscle. Lane 4,Colon.Lane 5,Thymus.
Lane 6, Spleen. Lane 7, Kidney. Lane 8, Liver. Lane 9, Small intestine.
Lane 10, Placenta.Lane 11, Lung.Lane 12, Peripheral blood leukocytes.
Expression of ∼1.8-kb MGC4607 transcripts was detected in all tissues
studied.
of these mutations led to MGC4607 haploinsufﬁciency.
Indeed, one of these mutations altered the initiation co-
don, and two other mutations deleted the ﬁrst exon of
this gene, leading to a nondetectable expression of one of
the two alleles. Five mutations led to premature stop co-
dons through direct nonsense, frameshifts or splice-site
mutation events. One mutation led to the spicing of exon
3 without a frameshift. The last mutation, L198R, a mis-
sense mutation, cosegregated with the affected phenotype
in family C002 and was not detected in the control panel;
complete sequencing of MGC4607 did not detect any
other mutation or aberrant subsequent splice eventwithin
family C002. On the basis of these data, we considered
that this mutation might be causing the disease in this
family. However, that cannot yet be established deﬁnitely,
since we cannot exclude a rare polymorphism, especially
since the amino acid located at this position is not con-
served in the MGC4607 mouse ortholog.
We detected a mutation in 10 of 30 of our families.
The absence of mutation in the 20 additional families
is not unexpected, on the basis of previous linkage data.
Indeed, CCM is genetically heterogeneous, and multilo-
cus linkage data strongly suggested that only 20% of
families with CCM have linkage to the CCM2 locus
(Craig et al. 1998). Since these 30 families were initially
selected on the basis of a negative KRIT1 mutation
screening, one would have expected to detect ∼10 fami-
lies with mutations within this panel. Nevertheless, we
cannot exclude the possibility that we may have missed
a few mutations, including deletions and/or promotor
mutations. This may be the case for family C049, in
which we did not detect any mutation, although linkage
data were consistent with linkage to the CCM2 locus
and excluded linkage to CCM3. A complete deletion of
the CCM2 gene has been excluded in this family, as well
in the other 19 families without mutations, on the basis
of heterozygosity data; however, additional work will
be needed to exclude deletions of one or more exons.
Little is known yet about MGC4607. Its pattern of
expression at the transcriptional level appears quite
ubiquitous at present, and much has to be done to de-
cipher its function. Krit1 has been shown to interact
with rap1A, a small Ras-like GTPase protein, and with
ICAP1a, an integrin b1 modulator (Serebriiskii et al.
1997; Zhang et al. 2001; Zawistowski et al. 2002).
Future studies will help to determine if MGC4607 plays
a role in these pathways.
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